Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
- 1 March 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 11 (3), 397-407
- https://doi.org/10.1517/13543784.11.3.397
Abstract
Fondaparinux (Arixtra®, Sanofi-Synthélabo/Organon) is the first of a new class of antithrombotic agents distinct from low molecular weight heparins (LMWHs) and heparin. It is a chemically synthetic pentasaccharide mimicking the site of heparin that binds to antithrombin III (AT). It exhibits only factor (F) Xa (FXa) inhibitor activity via binding to AT, which in turn inhibits thrombin generation. In contrast to heparin and LMWH, plasma anti-Xa activity corresponds directly to levels of fondaparinux. It does not release tissue factor pathway inhibitor (TFPI). There is nearly complete bioavailability by the sc. route, rapid onset of action, a prolonged half-life in both iv. and sc. (14 - 20 h) dosing regimens and no metabolism preceding renal excretion. Phase IIb clinical studies have identified a dose of 2.5 mg once-daily for prophylaxis of venous thrombosis. Four Phase III studies (n > 7000) have demonstrated a combined 50% relative risk reduction of venous thromboembolic events in orthopaedic surgery pat...Keywords
This publication has 32 references indexed in Scilit:
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryNew England Journal of Medicine, 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic AgentCardiovascular Drug Reviews, 1997
- Antithrombin-mediated Inhibition of Factor Vlla-Tissue Factor Complex by the Synthetic Pentasaccharide Representing the Heparin Binding Site to AntithrombinThrombosis and Haemostasis, 1996
- Treatment with LMWHs inhibits factor VIIa generation during in vitro coagulation of whole bloodThrombosis Research, 1996
- The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor XaThrombosis and Haemostasis, 1995
- Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycansThrombosis Research, 1994
- Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbitsThrombosis Research, 1994
- Synthesis of heparin fragments: A methyl α-pentaoside with high affinity for antithrombin IIICarbohydrate Research, 1987
- Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: Evidence for conformational peculiarity of the sulfated iduronate residueBiochemical and Biophysical Research Communications, 1985